| abstract |
The present disclosure presents, in some aspects, immunotherapy (eg, adoptive cell therapy, eg T cell therapy) and immunity such as structural or functional analogs or derivatives of thalidomide and / or inhibitors of E3-ubiquitin ligase. With respect to methods, compositions and uses, including with regulatory compounds. The methods, compositions and uses provided are combined with T cell therapies such as genetically engineered T cell therapies that include cells engineered on recombinant receptors such as chimeric antigen receptor (CAR) expressing T cells. Includes methods, compositions and uses for combination therapies comprising administering or using one or more immunomodulatory compounds. Also provided are compositions for use in the process, methods of administration to the subject, articles of manufacture and kits. In some aspects, the method and cell characteristics are an increase or improvement in the activity, potency, persistence, augmentation and / or proliferation of endogenous T cells mobilized by T cells for adoptive cell therapy or immunotherapeutic agents. I will provide a. |